{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:31:00Z","timestamp":1762673460372},"reference-count":59,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1586\/14787210.3.1.9","type":"journal-article","created":{"date-parts":[[2005,3,13]],"date-time":"2005-03-13T01:27:27Z","timestamp":1110677247000},"page":"9-21","source":"Crossref","is-referenced-by-count":16,"title":["Tipranavir: a novel second-generation nonpeptidic protease inhibitor"],"prefix":"10.1586","volume":"3","author":[{"given":"Vijayabhaskar Reddy","family":"Kandula","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Homayoun","family":"Khanlou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Farthing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"Palella","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00126334-199905010-00008","volume":"21","author":"Chiasson","year":"1999","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1328-1332.2000"},{"key":"CIT0004","unstructured":"Schwartz R, Kazanjian P, Slater Let al.Resistance to tipranavir is uncommon in a randomized trial of tipranavir\/ritonavir in multiple-PI-failure patients (BI 1182.2).9th Conference on Retroviruses and Opportunistic Infections.Seattle, WA, USA, 24\u201328 February 2002 (Abstract 562-T)."},{"key":"CIT0005","first-page":"S106","volume":"7","author":"Mccallister","year":"2002","journal-title":"Antivir. Ther."},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.288.2.222","volume":"288","author":"Yeni","year":"2002","journal-title":"J. Am. Med. Assoc."},{"key":"CIT0007","unstructured":"US Department of Health and Human Services.Guidelines for the use of Antiretroviral Agents in HIV-Infected Adults and Adolescents.US Department of Health and Human Services, WA, USA (2002)."},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/00126334-200202011-00004","volume":"29","author":"Keiser","year":"2002","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1086\/314675","volume":"179","author":"Wit","year":"1999","journal-title":"J. Infect. Dis."},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJM199912163412501","volume":"341","author":"Staszewski","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00126334-200202011-00003","volume":"29","author":"Acosta","year":"2002","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"CIT0012","unstructured":"Cahn P, Casiro A, Puentes Tet al.Continued indinavir (800 mg t.i.d.) versus switching to indinavir plus ritonavir (800\/100 mg b.i.d.) in HIV patients having achieved viral load suppression. A randomized study: the B.i.d. Efficacy and Safety Trial (BEST).1st IAS Conference on HIV Pathogenesis and Treatment.Buenos Aires, Argentina, 8\u201311 July 2001 (Abstract 60)."},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","volume":"346","author":"Walmsley","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"CIT0014","unstructured":"Feinberg J, Eron J, Bernstein Bet al.Once-daily vs. twice-daily Kaletra (lopinavir\/ritonavir) in antiretroviral-naive HIV+ patients: 72-week follow-up.The 14th International AIDS Conference.Barcelona, Spain, 7\u201312 July 2002 (Abstract Tupeb4445)."},{"key":"CIT0015","unstructured":"Eron JJ, Bernstein B, King Met al.Once-daily vs. twice-daily Kaletra (lopinavir\/ritonavir) in antiretroviral-naive HIV+ patients: 48-week follow-up.The 9th Conference on Retroviruses and Opportunisitc Infections.Seattle, WA, USA, 4\u201328 February 2002 (Abstract 409-W)."},{"key":"CIT0016","first-page":"S119","author":"Kempf","year":"2002","journal-title":"Antivir. Ther."},{"key":"CIT0017","unstructured":"Schumann D, Gathe J, Sanne I, Wood R, on behalf of the SOLO study team. Efficacy and safety of GW433908\/ritonavir once daily in therapy-naive subjects (The SOLO Study): 48-week results.6th International Congress on Drug Therapy in HIV Infection.Glasgow, UK, 17\u201321 November 2002 (Abstract PL14.4)."},{"key":"CIT0018","unstructured":"Elston R, Macmanus S, Yates Pet al.Lack of resistance to boosted 908 confirmed through 48 weeks of therapy in naive subjects.2nd International AIDS Society Conference on HIV Pathogenesis and Treatment.Paris, France, 13\u201316 July 2003 (Abstract 558)."},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.16.7462-7469.2001"},{"key":"CIT0020","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/00002030-200205030-00007","volume":"16","author":"Prado","year":"2002","journal-title":"AIDS"},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1021\/jm960541s","volume":"39","author":"Thaisrivongs","year":"1996","journal-title":"J. Med. Chem."},{"key":"CIT0022","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1021\/jm9802158","volume":"41","author":"Turner","year":"1998","journal-title":"J. Med. Chem."},{"key":"CIT0023","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1021\/jm00018a023","volume":"38","author":"Thaisrivongs","year":"1995","journal-title":"J. Med. Chem."},{"key":"CIT0024","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1021\/jm00026a002","volume":"38","author":"Skulnick","year":"1995","journal-title":"J. Med. Chem."},{"key":"CIT0025","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1128\/AAC.41.5.1058","volume":"41","author":"Poppe","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009080-00009"},{"key":"CIT0027","unstructured":"Borin MT, Wang Y, Schneck DW, Li H, Brewer JE, Daenzer CL. Multiple-dose, safety, tolerance, and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers.5th Conference on Retroviruses and Opportunistic Infections.Chicago, IL, USA, 1\u20135 February 1998 (Abstract 648)."},{"key":"CIT0028","unstructured":"Meal TCB, Wang Y. The safety, tolerance, pharmacokinetics and efficacy of PNU-140690, a new nonpeptidic hiv protease inhibitor, in a Phase I\/II study.12th World AIDS Conference.Geneva, Switzerland, 28 June\u20133 July 1998 (Abstract 41176)."},{"key":"CIT0029","unstructured":"Baldwin JR, Borin MT, Wang Y, Schneck DW, Hopkins NK. Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers.5th Conference on Retroviruses and Opportunistic Infections.Chicago, IL, USA, 1\u20135 February 1998 (Abstract 649)."},{"key":"CIT0030","unstructured":"Van Heeswijk R, Sabo JP, Cooper Cet al.The Pharmacokinetic interaction between tipranavir\/ritonavir 500 M\/200 M b.i.d. (tipranavir\/R) and atorvastatin, antacid and CYP3A4 in healthy volunteers.5th International Workshop on Clinical Pharmacology of HIV Therapy.Rome, Italy, 1\u20133 April 2004 (Poster 5.2)."},{"key":"CIT0031","unstructured":"Wang Y, Daenzer C, Wood Ret al.(BI 1182.3). The safety, efficacy and viral dynamics analysis of tipranavir, a new-generation protease inhibitor, in a Phase II study in antiretroviral-naive HIV-1-infected patients.7th Conference on Retroviruses and Opportunistic Infections.San Francisco, LA, USA, 30 January\u20132 February 2000 (Abstract 673)."},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200404010-00007"},{"key":"CIT0033","unstructured":"Gathe J, Veronika M, Kohlbrenner VMet al.Tipranavir\/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients.10th Conference on Retroviruses and Opportunistic Infections.Boston, MA, USA, 10\u201314 February 2003 (Abstract 179)."},{"key":"CIT0034","unstructured":"Yeni P, Macgregor T, Gathe Jet al.Correlation of viral load reduction and plasma levels in multiple protease inhibitor experienced patients taking tipranavir\/ritonavir in a Phase IIB trial: BI 1182.52.10th Conference on Retroviruses and Opportunistic Infections.Boston, MA, USA, 10\u201314 February 2003 (Abstract 528)."},{"key":"CIT0035","unstructured":"Baldwin JR, Borin MT, Ferry JJet al.pharmacokinetic interaction between hiv protease inhibitors tipranavir and ritanovir.39th Interscience Conference on Antimicrobial Agents and Chemotherapy.San Francisco, LA, USA, 26\u201329 September 1999 (Abstract 657)."},{"key":"CIT0036","unstructured":"McCallister J, Sabo J, Mayers DL, Galitz L. An open-label steady-state investigation of the pharmacokinetics (PK) of tipranavir (tipranavir) and ritonavir (ritonavir) and their effects on cytochrome P450 (3A4) activity in normal healthy volunteers (BI 1182.5).9th Conference on Retroviruses and Opportunistic Infections.Seattle, WA, USA, 24\u201328 February 2002 (Abstract 434-W)."},{"key":"CIT0037","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1128\/AAC.37.5.1095","volume":"37","author":"Japour","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"CIT0038","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1128\/AAC.41.11.2367","volume":"41","author":"Chong","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"CIT0039","unstructured":"Doyon L, Tremblay S, Cartier M, Cordingley MG.In vitrosusceptibility of HIV-1 to tipranavir.11th International HIV Drug Resistance Workshop.Seville, Spain, 2\u20135 July 2002."},{"key":"CIT0040","unstructured":"Doyon L, Tremblay S, Wardrop Eet al.Characterization of HIV-1 showing decreased susceptibility to tipranavir and their inhibition by tipranavir-containing drug mixtures.12th International Drug Resistance Workshop.Los Cabos, Mexico, 10\u201313 June 2003 (Abstract 14)."},{"key":"CIT0041","unstructured":"Slater L, Farthing C, Jayaweera DJet al.(BI 1182.4 Study Team). Safety and efficacy of tipranavir, a nonpeptidic protease inhibitor, in pi-failure patients (late-breaker).41st Interscience Conference On Antimicrobial Agents And Chemotherapy.Chicago, IL, USA, 16\u201319 December 2001 (Abstract LB15)."},{"key":"CIT0042","unstructured":"Jayaweera DJ, Slater L, Haas D, Farthing C, Mckinley G, Schwartz R. Susceptibility profile of tipranavir at baseline and subsequent virologic response in a cohort of patients with single protease inhibitor failure.2nd International HIV Workshop On Management Of Treatment-Experienced Patients.San Diego, CA, USA, 26\u201327 September 2002 (Abstract P5)."},{"key":"CIT0043","unstructured":"Mayers DL, Kohlbrenner VM, Dohnanyil Cet al.The inhibitory quotient (IQ) of tipranavir\/ritonavir (tipranavir\/R) in triple-class experienced HIV infected patients (BI 1182.52).The 2nd IAS Conference on HIV Pathogenesis and Treatment.Paris, France, 13\u201316 July (2003) (Abstract 9)."},{"key":"CIT0044","doi-asserted-by":"crossref","unstructured":"Cooper D, Hall D, Jayaweera DJet al.Baseline phenotypic suceptibility to tipranavir\/ritonavir is retained in isolates from patients with multiple protease inhibitor experience (BI 1182.52).10th Conference on Retroviruses and Opportunistic Infections.Boston, MA, USA, 10\u201314 February 2003 (Abstract 596).","DOI":"10.2165\/00128413-200313780-00026"},{"key":"CIT0045","unstructured":"Squires K, Mccallister S, Lazzarin Aet al.Tipranavir\/ritonavir demonstrates a robust resistance profile in multiple protease inhibitor experienced patients: correlation of baseline genotype and antiviral activity (BI 1182.524).The 2nd IAS Conference on HIV Pathogenesis and Treatment.Paris, France, 13\u201316 July 2003 (Abstract 812)."},{"key":"CIT0046","unstructured":"Hall D, Mccallister S, Neubacher D, Kraft M, Mayers DL. Characterization of treatment-emergent resistant mutations in two Phase II studies of tipranavir.XII International HIV Drug Resistance Workshop.Los Cabos, Mexico, 10\u201313 June 2003."},{"key":"CIT0047","unstructured":"Curry R, Markowitz M, Slater Let al., (BI Study Team). Safety and efficacy of tipranavir, a nonpeptidic protease inhibitor, in multiple-PI-failure patients (BI 1182.2).1st IAS Conference on HIV Pathogenesis and Treatment.Buenos Aires, Argentina, 8\u201311 June 2001 (Abstract 3)."},{"key":"CIT0048","unstructured":"Neubacher D, Markowitz M, Slater L, Curry R, Kohlbrenner VM, Mccallister S. Long-term 80-week follow-up of highly treatment-experienced (HTE) patients on tipranavir-based antiretroviral therapy (BI 1182.2).9th European AIDS Conference.Warsaw, Poland, 25\u201329 October 2004 (Abstract 7.2\/3)."},{"key":"CIT0049","unstructured":"Hicks C, for The RESIST-1 Study Team. RESIST-1: Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir: Phase III comparison of tipranavir\/R and standard-of-care boosted-comparator PI (CPI\/R) at 24 Weeks.44th Interscience Conference on Antimicorbial Agents and Chemotherapy.Washington DC, WA, USA, 30 October\u20132 November 2004 (Abstract H-1137a)."},{"key":"CIT0050","unstructured":"Curry K, Samauels C, Leith Jet al.(BI1182.51 Study Team). Pharmacokinetics and safety of tipranavir\/ritonavir alone or in combination with saquinavir, amprenavir, or lopinavir. Interim analysis of BI1182.51.5th International Workshop on Clinical Pharmacology of HIV Therapy.Rome, Italy, 1\u20133 April 2004 (Abstract 5.1)."},{"key":"CIT0051","unstructured":"Valdez H, Sabo J, Wruck Jet al.Tipranavir excretion mass balance and metabolite profile when coadministered with ritonavir.44th Interscience Conference on Antimicrobial Agents and Chemotherapy.Washington DC, WA, USA, 30 October\u20132 November 2004 (Abstract A-455)."},{"key":"CIT0052","unstructured":"Roszko PJ, Curry K, Brazina Bet al.Standard doses of efavirenz (EFV), zidovudine (ZDV), tenofovir (TDF), and didanosine (Ddi) may be given with tipranavir\/ritonavir.2nd IAS Conference on HIV Pathogenesis and Treatment.Paris, France, 13\u201316 July 2003 (Abstract 865)."},{"key":"CIT0053","unstructured":"Sabo PJ, Macgregor T, Lamson M, Baldwin J, Borin M, Harris F. Pharmocokinetics of tipranavir and nevirpaine.10th Annual Canadian Conference on HIV\/AIDS Research.Toronto, Canada, 31 May\u20133 June 2001 (Abstract 249P)."},{"key":"CIT0054","unstructured":"Pharmacokinetic drug interaction screen of the three doses of tipranavir\/ritonavir (tipranavir\/R) in HIV-infected patients on stable highly active antiretroviral therapy (HAART).HIV DART.Naples, FL, USA, 15\u201319 December 2002."},{"key":"CIT0055","unstructured":"Van Heeswijk R, Sabo JP, Macgregor TRet al.The effect of tipranavir\/ritonavir 500\/200 mg b.i.d. (tipranavir\/R) on the pharmacokinetics of fluconazole in healthy volunteers.5th International Workshop on Clinical Pharmacology of HIV Therapy.Rome, Italy, 1\u20133 April 2004 (Abstract 4.8)."},{"key":"CIT0056","unstructured":"Van Heeswijk R, Sabo J, Macgregor TRet al.The effect of tipranavir\/ritonavir 500\/200 mg b.i.d on the pharmacokinetics of clarithromycin in healthy volunteers.44th Interscience Conference on Antimicrobial Agents and Chemotherapy.Washington, WA, USA, 30 October\u20132 November 2004 (Abstract A-457)."},{"key":"CIT0057","unstructured":"Van Heeswijk R, Sabo J, Macgregoret al.The pharmacokinetic interaction between single-dose rifabutin and steady-state tipranavir\/ritonavir 500\/200 mg b.i.d in healthy volunteers.44th Interscience Conference on Antimicrobial Agents and Chemotherapy.Washington DC, WA, USA, 30 October\u20132 November 2004 (Abstract A-456)."},{"key":"CIT0058","unstructured":"UNAIDS: HIV\/AIDS: A unique global threat www.unaids.org\/unaids\/en\/about+unaids\/what+is+unaids\/hiv_aids_a+unique+global+threat.asp (Accessed January 2005)"},{"key":"CIT0059","unstructured":"UNAIDS: AIDS Epidemic Update 2003 www.unaids.org\/unaids\/en\/resources\/publications\/corporate+publications\/aids+epidemic+update+-+december+2003.asp# (Accessed January 2005)"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14787210.3.1.9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T16:50:46Z","timestamp":1683046246000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14787210.3.1.9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1586\/14787210.3.1.9"],"URL":"https:\/\/doi.org\/10.1586\/14787210.3.1.9","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}